MATINAS 1 BIOPHARMA Corporate Presentation May 2022 Forward-Looking Statement This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, cash flow and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are stat ...

Matinas BioPharma Holdings Inc. (NYSE:MTNB) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Jerome Jabbour - Chief Executive Officer Theresa Matkovits - Chief Development Officer Terry Ferguson - Chief Medical Officer Keith Kucinski - Chief Financial Officer Peter Vozzo - Investor Relations Conference Call Participants Bert Hazlett - BTIG Operator Welcome to the Matinas BioPharma First Quarter 2022 Results Conference Call. At this time, all participants are in a listen-only m ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other juri ...

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q4 2021 Earnings Conference Call March 8, 2022 8:30 AM ET Company Participants Peter Vozzo - Investor Relations Jerome Jabbour - Chief Executive Officer Keith Kucinski - Chief Financial Officer Terry Ferguson - Chief Medical Officer Conference Call Participants Robert Hazlett - BTIG Greg Fraser - Truist Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are designed to ...

Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other jurisdicti ...

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q3 2021 Earnings Conference Call November 8, 2021 8:30 AM ET Company Participants Peter Vozzo - Investor Relations Jerome Jabbour - Chief Executive Officer Keith Kucinski - Chief Financial Officer Terry Ferguson - Chief Medical Officer Terry Matkovits - Chief Development Officer Raphael Mannino - Chief Scientific Officer Conference Call Participants Robert Hazlett - BTIG Greg Fraser - Truist Operator Greetings and welcome to Matinas BioPharma's Third Quarter 2021 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other ...

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q2 2021 Results Conference Call August 10, 2021 8:00 AM ET Company Participants Jerome Jabbour ??? Chief Executive Officer Peter Vozzo ??? Investor Relations Keith Kucinski ??? Chief Financial Officer Terry Ferguson ??? Chief Medical Officer Terry Matkovits ??? Chief Development Officer Raphael Mannino ??? Chief Scientific Officer Unidentified Company Representative ??? Company Participant Conference Call Participants Robert Hazlett ??? BTIG Greg Fraser ??? Truis ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 1545 Route 206 South, Suite 302 Bedminster, New Jersey 07921 (Address of principal executive offices) (Zip Code) 908-484-8805 (Registrant's telephone number, including area code) Securities registered ...

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q1 2021 Earnings Conference Call May 10, 2021 8:00 AM ET Company Participants Peter Vozzo - Investor Relations Jerome Jabbour - Chief Executive Officer Keith Kucinski - Chief Financial Officer Conference Call Participants Robert Hazlett - BTIG Yasmeen Rahimi - Piper Sandler Gregory Fraser - Truist Securities Operator Hello, and welcome to the Matinas BioPharma's Q1 2021 Results Conference Call and Webcast. At this time, all participants are in a listen-only mode. ...